英国Cyprotex  
Cyprotex是ADME数据和药动学预测服务的专业供应商。该公司特有的Cloe(R)Screen技术将巧妙的方案与先进的自动化操作相结合，使得Cyprotex能够同时提供高品质、具有成本效益的数据和较短的周转时间。深入地研究需要更加灵活的方案，而Cloe(R)Select的推出确保了Cyprotex能够将其产品拓展至深入研究的后期。Cyprotex的Cloe(R)预测服务在生理药动学(PB-PK)建模和定量构效关系(QSAR)建模技术领域还拥有全面的专长。Cloe(R)Screen、Cloe(R)Select和Cloe(R)Predict的结合为实验筛选和预测提供了一个综合解决方案，满足了该公司庞大且多样化的客户群的需求。

Cyprotex is a world renowned preclinical discovery/development contract research organisation with a core focus
in analysing the ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic properties
of potential new drugs.
Cyprotex is based in Macclesfield, nr. Manchester in the UK and is listed on the AIM market of the London Stock Exchange (CRX). Our company was established in 1999 and we work with in excess of 200 partners ranging from small Biotechs to large Pharma. We provide support for a wide range of experimental and computational ADME and PK services extending from early drug discovery through to IND submission.

Our core capabilities include:

Our unique Cloe® Screen platform which is based on state of the art robotics and a highly sophisticated customised information management system. This dramatically reduces the cost and time in generating data whilst ensuring excellent reproducibility of data.
Our Cloe® Select experimental service which provides support for later stage ADME and DMPK studies.
A range of predictive technologies available under Cloe® Predict which take advantage of our extensive expertise in PBPK and QSAR modelling. Our proprietary Cloe® PK software product integrates core ADME and physicochemical properties to predict whole body pharmacokinetics.